Debu Tripathy on Monitoring Patients with Breast Cancer on Oral Oncolytics

Video

Debu Tripathy on the management of patients with breast cancer on oral oncolytics.

Debu Tripathy, MD, Chair of Breast Medical Oncology at MD Anderson Cancer Center, discusses the important points for nurses to keep in mind when managing patients with breast cancer who are taking oral oncolytics.

The oral agents such as palbociclib (Ibrance) and everolimus (Afinitor) can come with side effects that cause patients to discontinue treatment. These are side effects such as mouth ulcers, with everolimus, and fatigue, with palbociclib. Nurses can be sure to anticipate these side effects, educate the patients on the possibilities, and monitor patients closely throughout treatment.

Newsletter

Stay up to date on recent advances in oncology nursing and patient care.

Subscribe Now!
Recent Videos
2 experts are featured in this series.
Image of a man in a suit standing in front of a blue Oncology Nursing News backdrop
2 experts are featured in this series.
Image of a woman with shoulder-length black hair wearing headphones and a white sweater
Image of a woman with a blue background
5 experts in this video
5 experts in this video
Image of a man in scrubs with short hair and glasses
Photo of a woman with brown hair and bangs, surrounded by a blue border
Related Content
Close-up photo of a patient's hand being held by a the hands of a health care professional

Social Health Determinants Impact Psychoneurological Symptoms in BC Survivors

Kyle Doherty
April 11th 2025
Article

Social determinants of health like transportation and financial increased the occurrence of psychoneurological symptoms in breast cancer survivors.

Improving The Rate Of Accurate Inflammatory Breast Cancer Diagnoses

Improving The Rate Of Accurate Inflammatory Breast Cancer Diagnoses

Lindsay Fischer
October 2nd 2023
Podcast

Ryan Tamargo, NP, AONCP, discusses the launch of an online inflammatory breast cancer scoring system tool.

Line illustration of an IV drip in gold on a dark blue background

FDA Approves Denosumab Biosimiliars for Prior Authorized Indications

Tim Cortese
March 13th 2025
Article

Two denosumab biosimilars have been approved by the FDA for all previously approved uses for the reference drugs in cancers and osteoporosis.

The Vitals

Nurse Practitioners Weigh in on Data From the San Antonio Breast Cancer Symposium

Lindsay Fischer
January 16th 2023
Podcast

Loyda Braithwaite, MSN, RN, AGPCNP-BC, AOCNP; and Jamie Carroll, APRN, CNP, MSN, highlight presentations from the 2022 San Antonio Breast Cancer Symposium that will influence oncology nursing practice.

Line illustration of a breast with tissue on a cerulean background

Frontline Camizestrant Combo Increases PFS In Breast Cancer Subtypes

Kyle Doherty
March 5th 2025
Article

Camizestrant with a CDK4/6 inhibitor was well tolerated and effective as first-line therapy for patients with ESR1-mutated, HR-positive/HER2-negative advanced breast cancer.

Blue rendering of a person with breast tissue highlighted in orange

T-DM1 Further Improves DFS and OS vs Trastuzumab in HER2-Positive Early Breast Cancer

Bridget Hoyt
February 20th 2025
Article

T-DM1 reduced risk of invasive disease events and death compared with trastuzumab in HER2-positive early breast cancer with residual invasive disease after neoadjuvant therapy.